177 Lu PSMA Treatment for Prostate Cancer (Update: FDA approved on 3/23/22)

Lutetium-177: PSMA Guided Treatment | #ProstateCancer | #MarkScholzMD | #PCRIПодробнее

PSMA Scans & Pluvicto (lutetium-177) in 2022 | Geoffrey Johnson, MD, PhD | PCRI Conference 2022Подробнее

PSMA & Lutetium-177 in 2022 | Eugene Kwon, MD | DIY Combat Manual for Beating Prostate Cancer Part 4Подробнее

New FDA Approved: Pluvicto (Lutetium-177) for Advanced Prostate Cancer | Mark Scholz, MD | PCRIПодробнее

Lu-PSMA Radioligand TherapyПодробнее

177Lu-PSMA-617 for the early treatment of prostate cancerПодробнее

Lutetium-177 PSMA therapyПодробнее

An Update on Lutetium-177 for Prostate Cancer | Thomas Hope, MD & Mark Moyad, MD, MPH | 2021 PCRIПодробнее

Lutetium 177: Targeted Treatment for Advanced Prostate Cancer ExplainedПодробнее

Lutetium-177 (Pluvicto) vs. PSMA-Actinium | #MarkScholzMD #AlexScholz #PCRIПодробнее

The Story Behind the FDA's Approval of PSMA for Prostate Cancer | Thomas Hope, MD & Mark Moyad, MDПодробнее

Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PCПодробнее

Spectrum News - Dr. Pliskin - Lutetium-177 PSMA treatment approved for late-stage prostate cancerПодробнее

ECLIPSE - A Randomized Phase 3 Trial for 177-Lu-PSMA-I&T in patients with mCRPCПодробнее

Safety and Efficacy of 177Lu-PSMA-617Подробнее

Treatment Updates for Advanced Prostate Cancer – 2023 ZERO Prostate Cancer SummitПодробнее

Real-world outcomes of 177Lu-PSMA-617 in mCRPCПодробнее

TheraP Trial of 177Lu-PSMA-617 Review | David VanderWeele, MD | ASCO22 Prostate Cancer UpdatesПодробнее

2024 Update | Lu-177 (Pluvicto), Actinium & New #ProstateCancer AntiBody | Dr. Nat Lenzo #AlexScholzПодробнее